Nature Medicine：iPSC神经细胞治疗脊髓损伤的临床试验长期随访数据发布
Merged summary
TL;DR - A first-in-human phase 1 trial found iPSC-derived neural progenitor cell transplantation feasible and safe in four patients with subacute complete spinal cord injury over 2–4 years. Preliminary neurological improvements support larger clinical studies, but efficacy remains unproven.
- No tumors or graft-related adverse events were observed, and imaging showed stable graft locations.
- At 52 weeks, motor scores improved by a median of 13 points, with a range of 10–40.
- Two patients improved from AIS grade A to C and A to D, respectively.
- The study used short-term immunosuppression and primarily evaluated safety; the four-patient sample limits efficacy conclusions.
Sources (1)
Nature Medicine：iPSC神经细胞治疗脊髓损伤的临床试验长期随访数据发布
TL;DR - A first-in-human phase 1 trial found iPSC-derived neural progenitor cell transplantation feasible and safe in four patients with subacute complete spinal cord injury over 2–4 years. Preliminary neurological improvements support larger clinical studies, but efficacy remains unproven.
- No tumors or graft-related adverse events were observed, and imaging showed stable graft locations.
- At 52 weeks, motor scores improved by a median of 13 points, with a range of 10–40.
- Two patients improved from AIS grade A to C and A to D, respectively.
- The study used short-term immunosuppression and primarily evaluated safety; the four-patient sample limits efficacy conclusions.